Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 12, 2011 - Issue 17
Submit an article Journal homepage
346
Views
14
CrossRef citations to date
0
Altmetric
Drug Evaluations

Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia

Ethan Rubinstein University of Manitoba, Faculty of Medicine, Section of Infectious Diseases, 543 – 745 Basic Medical Sciences Building, Winnipeg MB R3E 0J9, Canada+1 204 977 5680/1; +1 204 789 3926; [email protected]
,
G Ralph CoreyDuke Clinical Research Institute, Durham, NC, USA; Duke University Medical Center, Division of Infectious Diseases, Durham, NC, USA
,
Martin E StryjewskiDuke Clinical Research Institute, Durham, NC, USA; Centro de Educación Médica e Investigaciones Clínicas ‘Norberto Quirno’, Department of Medicine and Division of Infectious Diseases, Buenos Aires, Argentina
&
Zeina A Kanafani American University of Beirut Medical Center, Division of Infectious Diseases, Beirut, Lebanon
Pages 2737-2750 | Published online: 11 Nov 2011

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Matteo Bassetti & Elda Righi. (2016) Safety profiles of old and new antimicrobials for the treatment of MRSA infections. Expert Opinion on Drug Safety 15:4, pages 467-481.
Read now
Tamara Nawar & Zeina A Kanafani. (2015) Telavancin (VIBATIV) for the treatment of complicated skin and skin structure infections. Expert Review of Anti-infective Therapy 13:7, pages 825-833.
Read now
Candace Y Hooper & Winter J Smith. (2012) Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA). Therapeutics and Clinical Risk Management 8, pages 131-137.
Read now
Yoav Keynan & Ethan Rubinstein. (2012) Telavancin in the treatment of invasive Gram-positive infections. Clinical Audit 4, pages 25-29.
Read now

Articles from other publishers (10)

Leonard R. DuncanHelio S. SaderMichael D. HubandRobert K. FlammRodrigo E. Mendes. (2020) Antimicrobial Activity of Telavancin Tested In Vitro Against a Global Collection of Gram-Positive Pathogens, Including Multidrug-Resistant Isolates (2015–2017) . Microbial Drug Resistance 26:8, pages 934-943.
Crossref
François Lebreton & Vincent Cattoir. 2019. Bacterial Resistance to Antibiotics – From Molecules to Man. Bacterial Resistance to Antibiotics – From Molecules to Man 51 80 .
Biswadeep Das, Chayna Sarkar, Debasmita Das, Amit Gupta, Arnav Kalra & Shubham Sahni. (2017) Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens. Therapeutic Advances in Infectious Disease 4:2, pages 49-73.
Crossref
Junlan Chuan, Yuan Zhang, Xia He, Yuxuan Zhu, Lei Zhong, Dongke Yu & Hongtao Xiao. (2016) Systematic Review and Meta-Analysis of the Efficacy and Safety of Telavancin for Treatment of Infectious Disease: Are We Clearer?. Frontiers in Pharmacology 7.
Crossref
Bin Cao, Thuan T. Tan, Edwin Poon, Jann-Tay Wang, Suresh Kumar, Chong H. Kin Liam, Kamal Ahmed, Patrick Moral, Haibo Qiu, Marie Yvette Barez, Latre Buntaran, Oloan E. Tampubolon & Visanu Thamlikitkul. (2015) Consensus statement on the management of methicillin-resistant S taphylococcus aureus nosocomial pneumonia in Asia . The Clinical Respiratory Journal 9:2, pages 129-142.
Crossref
Ethan Rubinstein & Yoav Keynan. (2014) Vancomycin Revisited – 60 Years Later. Frontiers in Public Health 2.
Crossref
Stefano Fagiuoli, Agostino Colli, Raffaele Bruno, Antonio Craxì, Giovanni Battista Gaeta, Paolo Grossi, Mario U. Mondelli, Massimo Puoti, Evangelista Sagnelli, Stefania Stefani, Pierluigi Toniutto & Patrizia Burra. (2014) Management of infections pre- and post-liver transplantation: Report of an AISF consensus conference. Journal of Hepatology 60:5, pages 1075-1089.
Crossref
Lesley J. Scott. (2013) Telavancin: A Review of Its Use in Patients with Nosocomial Pneumonia. Drugs 73:16, pages 1829-1839.
Crossref
Admantia Liapikou, Laia Fernandez & Antoni Torres. (2012) Telavancin in the treatment of nosocomial pneumonia: review of the clinical evidence. Clinical Investigation 2:9, pages 939-948.
Crossref
Alberto Sandiumenge & Jordi Rello. (2012) Ventilator-associated pneumonia caused by ESKAPE organisms. Current Opinion in Pulmonary Medicine 18:3, pages 187-193.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.